Bemarituzumab for resectable stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an experimental drug (bemarituzumab) that targets a protein called FGFR2b in stomach cancer. It is given along with standard chemotherapy before and after surgery, to see if it helps reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a sample of your tumor available for testing.
- Your cancer must be stomach or gastroesophageal junction cancer that has not spread and can be removed with surgery.
- You must be scheduled to receive chemotherapy (FLOT) before and after surgery.
- Your tumor must test positive for high levels of FGFR2b protein.
- You must be in generally good health (able to do light activity).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of two targeted drugs (Envafolimab and Fruquintinib) plus chemotherapy given before surgery for certain types of stomach cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of three drugs (envollizumab, fruquintinib, and chemotherapy) given before surgery, to see if it can shrink stomach cancer enough to make it removable. It compares this combination to chemotherapy alone.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
This trial tests a new combination of chemotherapy and an immunotherapy drug (durvalumab) given before surgery for stomach or gastroesophageal junction cancer. The goal is to see if it shrinks the tumor and improves outcomes.
Hear when a new GastroEsophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.